Imeglimin Hydrochloride
Indications
The results of the clinical studies of Imeglimin in patients with type 2 diabetes mellitus demonstrated the promising efficacy of Imeglimin tablet both in monotherapy and combination therapies and indicated its acceptable safety. Based on these results, the proposed indication of "type 2 diabetes mellitus" is acceptable.
Pharmacology
Imeglimin's mechanism of action involves dual effects:
- Amplification of glucose-stimulated insulin secretion (GSIS) and preservation of β-cell mass; and
- Enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle.
Dosage & Administration
In general for adults 2 tablets (1,000 mg) at a time, twice a day in the morning and evening. Below instructions should be followed strictly.
If a dose is missed, the missed dose should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped and regular dosing schedule should be continued. Two doses should never be taken at one time.
If more than prescribed dose taken accidentally, consult with your doctor immediately
If a dose is missed, the missed dose should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped and regular dosing schedule should be continued. Two doses should never be taken at one time.
If more than prescribed dose taken accidentally, consult with your doctor immediately
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Contraindications
Imeglimin tablets are contraindicated in patients with:
- Hypersensitivity to the drug or any of its components.
- Severe ketosis, diabetic coma or pre-coma and also for immediate remedy in type 1 diabetes of hyperglycemias with infusion and insulin.
Side Effects
The most commonly reported side effects include nausea, diarrhea and constipation. Weakness, hungry feeling, sweating (hypoglycaemia) may also occur.
Pregnancy & Lactation
Pregnancy: The safety of this product in pregnant women has not been established. Imeglimin should be used in pregnant women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.
Lactation: Breast-feeding must be discontinued during administration of this product in lactating women (transfer to milk in animal studies has been reported).
Lactation: Breast-feeding must be discontinued during administration of this product in lactating women (transfer to milk in animal studies has been reported).
Precautions & Warnings
This medicine may cause hypoglycemic symptoms. Therefore pay close attention while working at heights, drive a car, or operate dangerous machinery.
If hypoglycemic symptoms occur, take sugar-containing foods or sugar. If you are taking alfa-glucosidase inhibitor (acarbose, voglibose, miglitol) in combination with this medicine, take glucose.
Dosage reduction might be required for patients with renal impairment, eGFR<15 ml/min/1.73 m2
If hypoglycemic symptoms occur, take sugar-containing foods or sugar. If you are taking alfa-glucosidase inhibitor (acarbose, voglibose, miglitol) in combination with this medicine, take glucose.
Dosage reduction might be required for patients with renal impairment, eGFR<15 ml/min/1.73 m2
Overdose Effects
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required.
Storage Conditions
Store below 30°C temperature and dry place, protected from light. Keep all medicines out of reach of children.